

Recommendation: Buy

Price target: 45.00 Euro


Upside potential: +13 percent

Share data

Share price	39.90 Euro (XETRA)
Number of shares (in m)	5.69
Market cap. (in EUR m)	227.1
Enterprise Value (in EUR m)	236.5
Code	M7U
ISIN	DE000A0MSN11

Performance

52 week high (in EUR)	41.00
52 week low (in EUR)	11.00
3 m relative to CDAX	+9.2%
6 m relative to CDAX	+58.9%



Source: Capital IQ

Shareholder

Paladin Asset Management	5.4%
Management & supervisory board c.	24.0%
Freefloat	70.6%

Calendar

Annual report 2020	May 2021
Q1 results	31 May 2021

Changes in estimates

	2020e	2021e	2022e
Sales (old)	75.8	87.6	101.8
Δ in %	-	-	-
EBIT (old)	8.0	12.7	15.6
Δ in %	-	-	-
EPS (old)	0.86	1.38	1.72
Δ in %	-	-	-

Analyst

Niklas Bentlage
 +49 40 41111 37 85
 n.bentlage@montega.de

Publication

Comment 10. March 2021

New medium-term planning underpins Nynomic’s promising prospects in sustainable growth markets

Nynomic yesterday has published new medium-term targets. With a strong operating development accompanied by high growth momentum over the last quarters, it seemed realistic that the previous targets would be met in the short term. We therefore view this move as logical and feel confirmed in our positive view of the company.

New medium-term targets seem achievable: After the company had guided for sales of EUR 100m and EBIT of about EUR 15m as medium-term targets, the new planning provides for medium-term sales of around EUR 150m with an EBIT margin of at least 15%. The sales target is planned to be reached within the next approximately five years driven by both organic and inorganic growth. Based on the manifold fields of application in strongly growing end markets, we assume that sales of EUR 150.9m (CAGR 2020-2025e: 14.0%) can already be reached in 2025. As for the EBIT margin, it is conceivable that the threshold of 15% can be exceeded in 2022 (MONE: 15,3%). Consequently, the new targets appear to be feasible in our view.

Momentum in Life Science segment expected to remain good: We believe the Life Science segment plays a key role in the achievement of the new medium-term targets. The new framework agreement (volume of EUR 25.0m) with one of the most important existing customers, which the company had communicated at the end of October last year, should stress the need for solutions for spectroscopy analysis in medical engineering, in our view, and is to serve as a proof of concept for other companies. We therefore expect to see positive momentum in this segment in the coming quarters as well.

As well as the structurally growing core business with increasing large-scale orders from medical engineering, the continuous roll-out of handy spectroscopy devices should also significantly contribute to the envisaged development. In this respect, we see a particularly high potential in the miniaturised spectroscopy solution that detects counterfeit pharmaceuticals. The annual damage for large pharmaceutical groups caused by counterfeit medicines amounts to over EUR 10bn p.a. (source: EU Intellectual Property Office). As a result, we expect high willingness to invest in the solution of Nynomic on the part of global pharmaceutical groups.

We had anticipated a revision of the medium-term targets and had already adjusted our estimates right after the publication of preliminary results for 2020, so this is seen as a confirmation of our forecasts which are left unchanged.

Conclusion: Following the strong preliminary results for the last financial year, the adjustment of the medium-term planning is seen to provide a clear signal for the capital market as to how the company values its growth opportunities. We remain convinced of the company’s short and long-term promising prospects and confirm our buy recommendation with a price target of EUR 45.00.

FYend: 31.12.	2018	2019	2020e	2021e	2022e
Sales	68.9	64.9	78.5	87.6	101.8
Growth yoy	13.5%	-5.9%	21.0%	11.6%	16.2%
EBITDA	13.2	9.5	11.2	16.1	19.1
EBIT	11.9	6.4	8.0	12.7	15.6
Net income	8.6	4.4	4.5	7.9	9.8
Gross profit margin	65.0%	63.4%	63.0%	63.1%	63.2%
EBITDA margin	19.2%	14.7%	14.3%	18.3%	18.8%
EBIT margin	17.2%	9.9%	10.2%	14.5%	15.3%
Net Debt	9.6	20.2	2.8	-4.8	-13.6
Net Debt/EBITDA	0.7	2.1	0.3	-0.3	-0.7
ROCE	43.4%	13.9%	15.3%	24.7%	30.4%
EPS	1.71	0.87	0.86	1.38	1.72
FCF per share	0.13	0.29	1.15	1.57	1.77
Dividend	0.00	0.00	0.00	0.00	0.00
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
EV/Sales	3.4	3.6	3.0	2.7	2.3
EV/EBITDA	17.9	24.8	21.1	14.7	12.4
EV/EBIT	19.9	36.8	29.5	18.6	15.2
P/E	23.3	45.9	46.4	28.9	23.2
P/B	8.3	7.2	4.7	4.1	3.5

Source: Company data, Montega, CapitalIQ

Figures in EUR m, EPS in EUR, Price: 39.90


COMPANY BACKGROUND

The Nynomic AG was founded in 1995 under the name of m-u-t GmbH Meßgeräte für Medizin- und Umwelttechnik and is based in Wedel near Hamburg. The company's origins are in the system integration of spectroscopy in medical and biotechnology. Today, the group is the leading full-line supplier of non-contact optical measurement technology. Unlike the classical techniques, such a measurement process does not only analyse the pure geometry but also the properties of objects. For instance, it can measure attributes such as colour, temperature, density or chemical composition in a non-contact and non-destructive way. The company markets both independent brands and white label products. It has access to the most important sales markets through its eight internationally positioned subsidiaries, benefits from a local support of customers and a well-developed sales and logistics network.

As a system supplier of individual components as well as complete equipment, Nynomic attends to a wide range of OEMs in different end markets along the entire value chain. Thanks to the successfully implemented buy and build strategy of the past years, Nynomic can offer its diversified product portfolio to numerous fields of applications both in the B2B and the emerging B2C sector, e.g. around the smart home megatrend. Amongst others, measurement technology is used in medical technology, in the chemicals industry, pharmaceutical industry, agriculture, environmental technology, semiconductor industry as well as in a broad array of applications in the entire industrial sector. Some of the most important milestones in the company's history are shown below.

- 1995** Foundation of m-u-t GmbH with a focus on measurement devices for medical and environmental technology
- 2007** Conversion into a stock corporation and listing on the Frankfurt Stock Exchange
- 2007** Shareholding in tec5 AG (51%), a supplier of spectroscopy solutions
- 2008** Acquisition of the majority stake in Avantes Holding B.V. (51%), a manufacturer of fibre optic spectroscopy devices
- 2011** Increase in the stake in tec5 AG by another 44% to 95%
- 2012** Restructuring of the business units
- 2014** Outsourcing of the operating business to the m-u-t GmbH
- 2015** Replacement of the Executive Board by Maik Müller (CEO) and Fabian Peters (CFO)
- 2016** Majority stake in APOS GmbH (55%), a spectroscopy supplier for the wood processing industry and complete acquisition of tec5 AG
- 2017** Complete acquisition of Avantes Holding B.V. as well as majority stake and integration of LayTec AG (95.6%), a market leader for process-integrated measurement technology and MEMS-based spectral sensors
- 2018** Capital increase by way of contribution in kind and acquisition of the remaining shares in LayTec AG
- 2018** Change of name to Nynomic AG
- 2018** Entry into the B2C market through the acquisition of Spectral Engines Oy (75%) and first strategic order from the area of end devices for the B2C market from Bosch-Siemens-Hausgeräte GmbH
- 2019** Acquisition of LemnaTec GmbH, a specialist for plant phenotyping
- 2019** Entry into the market of infrared temperature measurement by the acquisition of Sensortherm GmbH
- 2020** Acquisition of the remaining stake in Spectral Engines Oy and integration into Spectral Engines GmbH

With its roughly 425 employees, Nynomic generated revenue of EUR 64.8m and EBIT of EUR 6.4m in FY 2019. The organigram below gives an overview of the group’s organisational structure.



Source: Company

Shareholdings

Nynomic accompanies its customers along the entire value chain and offers different degrees of vertical integration and individual product modifications via its subsidiaries. The Nynomic AG acts as a subordinate financial holding and fulfils strategic functions within the group. All shareholdings have the same technological focus and support the vertical integration.

- **Avantes Holding B.V.**, which was acquired in 2008, is the basis for optical measuring cells and spectrometers. The company which is specialised in the miniaturisation of spectroscopy devices and software solutions develops and produces spectrometers, light sources for UV/VIS/NIR, fibre-optics and accessories. In addition, the company adjusts equipment according to customer-specific requirements. The Avantes group has access to all important markets through its own subsidiaries, enabling the company to locally support its OEM customers. The products are used, for instance, in biotechnology, the chemical and food industries as well as in thin film analysis for the production of solar cells.
- The **tec5 AG** has been part of the Nynomic group since 2007 and manufactures high-quality products for the detector array spectroscopy of OEM components as well as drive electronics. The company also covers the next step of the value chain and combines individual parts from Avantes B.V. to create full systems, which are directly sold to OEM and industrial clients as a standard solution under the company’s own name. tec5 has also access to the most important end markets via its subsidiaries.
- Operating subsidiary **m-u-t GmbH** produces products for the permanent, non-contact and non-destructive optical measurement technology. Using its proprietary know-how, m-u-t GmbH transforms the products of other group companies into innovative applications. The resulting customised solutions are then produced, e.g. as series equipment, and sold into the market. The company has a broad product range which, amongst others, includes sensorics, laboratory automation, medical technology, and spectroscopy.
- **APOS GmbH** supplies Nynomic’s customers with spectroscopic measurement systems, specifically for the wood processing industry. APOS is the technology and know-how leader in this niche market and is focused on applications with a high scalability. The products are typically used in the wood products industry, in biomass power plants and other bulk material applications.

- The internationally active **LayTec AG** is the market-leading supplier of process-integrated measurement technology with a focus on laser and LED production. Since the company's acquisition in 2017, the company-specific solutions are also increasingly used in photovoltaic, surface coating and in the semiconductor industry. For instance, the products can be employed in the in-situ process control of LEDs and semiconductor lasers. They are also suited for the real-time analysis of manufacturing processes as optical in-line metrology in the solar cell industry. Another product from LayTec, a measurement system for VCSEL lasers (vertical cavity surface-emitting laser), is used for Face-ID technologies in smartphones.
- **Spectral Engines GmbH** (initially: Spectral Engines Oy) develops and produces extremely compact low-cost spectral sensors, which can be used both in industrial applications and in the consumer segment. By acquiring this company, Nynomic laid the foundation for its entry in the area of end devices for the B2C segment. The products of Spectral Engines can be used in mobile devices at a reasonable price and thus predominantly target applications in the fields of smart home, smart industry and smart agriculture. A quick and reliable measurement is guaranteed with the help of the patented MEMS interferometer, which is already used as a food scanner in smartphones. With the help of an app and the corresponding cloud-based software, data is synchronised in real-time and is consistently optimised by machine learning. Following the takeover of a majority stake (75%) in May 2018, Nynomic acquired the remaining stake of the company in May 2020. In the same year, parts of the operating business were relocated from Finland to Germany as Spectral Engines Oy was integrated into Spectral Engines GmbH.
- **LemnaTec GmbH** is a specialist for hardware and software systems for digital plant phenotyping. The company's solutions enable a contact-free analysis of plants thanks to complex sensor technology helping to determine both essential growth and quality characteristics (e.g. size, shape and colour as characteristics for shoot and root growth) as well as physiological parameters (e.g. water and nutrient content or photosynthesis). These analyses provide fundamental indicators for the breeding and optimisation of seeds and crops in modern industrial agriculture. The areas of application span from agrochemistry, agronomy and plant research to practical breeding and include both small applications in the laboratory and large-scale installations for greenhouses and open fields.
- **Sensortherm GmbH** is a specialist in infrared measuring technology and offers numerous applications for non-contact, precise and quick temperature measurements. With an experience of more than 30 years the company is an industry-wide technology leader in this market. The pyrometers developed by Sensortherm are among the world's most efficient measuring devices of this kind thanks to their ability of a fully digital signal processing and signal output. Amongst others, pyrometers are used to control and regulate the process temperatures in laser systems. For this reason, they are of central importance for the steel industry, for instance, to pave the way for the best possible product quality by avoiding temperature deviations.

Segment analysis

Nynomic's operating business activities are divided in the Life Science, Green Tech and Clean Tech reporting segments.


Life Science (21% of total revenue in 2019): The products in this segment are mainly used in the pharma industry, in medical technology and biotechnology. The core products are optical sensors, spectroscopy systems and automation solutions for laboratories and research institutes, which can be used in a wide array of applications. Future potential, e.g. in research, is tapped by patent and licensing rights in analytical engineering.

Green Tech (16%): This segment develops and produces individual solutions for agriculture, specifically for applications in the area of intelligent farming. The increasingly industrialised and automated agricultural sector is perfectly aligned by efficiency-enhancing processes

such as the sensor-based analysis of soils and crop, the automated application of fertilizer, and radio-controlled animal feed. Additionally, the use of spectroscopy sensors supports producers in fulfilling regulatory quality requirements. The use of solar modules also falls under this segment.

Clean Tech (63%): This segment comprises a broad range of solutions for the industry sector. The broad areas of application span from individual optical sensors to customer-specific end-to-end solutions. The target markets are the chemical industry, food applications and the semiconductor industry. The automated inspection of processes helps to make the wafer and display production more efficient and guarantees a higher quality standard.

Sales by segment (2019)



Source: Company


Products

The group’s product solutions are all built on a spectral sensor technology platform. This measurement technology allows a non-destructive and non-contact analysis of product characteristics, as it measures the wavelength reflected by an object. These values can be specified in a connected database and the element can be clearly assigned. The procedure is universally applicable and can be easily integrated into the customers’ different process chains. Based on the relevant spectroscopy processes (UV/VIS/NIR/RAMAN/LIBS) the application solutions can be designed for a broad number of end markets. Thanks to Nynomic’s vertical integration the customers can choose between standard products and highly specific full systems, which increase the efficiency of production processes.

Nynomic also accompanies customers along the entire value chain in various end markets. The company has already gained significant experience in a multitude of industries and has a broad problem-solving expertise in the area of process-integrated online measurement technology. The end user is involved in the product development at a very early stage and benefits from Nynomic’s technology and know-how leadership. This leads to close customer relationships which often entail long-term contracts as well as exclusive supplier agreements.

Markets and sales

The branches and the sales network of Nynomic lead to a strong international distribution of sales. In addition to the production facilities, which are mainly located in Europe, the company has many subsidiaries and distribution facilities on other continents, supporting the local and direct customer service. In 2018, the group generated some 66% of sales in Europe. The remaining share is mainly generated in the USA, which accounted for some 26% of 2018 sales and is an important core market. The sales share in Europe is expected to increase further due to the full integration of the recently acquired Finnish Spectral Engines.



Source: Company

Experienced management

Maik Müller (CEO) has been appointed to the Executive Board of Nynomic AG in May 2015. He is responsible for Technology, Operations, and Research and Development. The graduate engineer (Dipl. Ingenieur) previously has been working in management positions for several years. In parallel, he was a member of the Executive Board of tec5 AG for many years, which today is a subsidiary of Nynomic. At that time, he contributed greatly to the establishment of the company. Maik Müller has many years of experience in management, especially in research and development as well as high-tech consulting. In 2018, he extended his contract prematurely until December 31, 2023.

Fabian Peters (CFO) has worked for the group since October 2013 and has been appointed to the Executive Board in 2015. The graduate tax consultant (Diplom-Finanzwirt) is responsible for Finance, Controlling, Organisation and Investor Relations. In parallel, he is Managing Director of m-u-t GmbH. Prior to joining the group, Fabian Peters was the CFO of the L&O group for many years, worked at Versatel AG in the field of finance and held several management positions in the insurance industry. In 2017, Fabian Peters' contract was prematurely extended until December 31, 2022.

Shareholder structure

As a result of the last capital increases in June and November 2020, which were used to finance further organic and external growth, the number of shares increased by 507,000 units in total. A further increase of 115,000 shares was caused by the stock option plan of the company in 2020 as management and supervisory board exercised 100,000 units in total. The share capital now amounts to EUR 5,692,000, divided into the same number of shares at a value of EUR 1.00 each. All the shares are bearer shares with voting rights. Roughly 24% of the share capital is held by members of the executive board and the supervisory board. With a stake of above 5%, Paladin Asset Management has been acting as a strategic anchor shareholder since June 2020. The remaining shares are free float.

APPENDIX

DCF Model

Figures in m	2020e	2021e	2022e	2023e	2024e	2025e	2026e	Terminal Value
Sales	78.5	87.6	101.8	117.1	133.5	150.9	169.0	173.2
<i>Change yoy</i>	21.0%	11.6%	16.2%	15.0%	14.0%	13.0%	12.0%	2.5%
EBIT	8.0	12.7	15.6	18.4	22.0	25.3	27.9	27.7
<i>EBIT margin</i>	10.2%	14.5%	15.3%	15.7%	16.5%	16.8%	16.5%	16.0%
NOPAT	5.4	8.8	10.8	12.8	15.4	17.7	19.5	19.4
Depreciation	3.2	3.3	3.6	3.9	4.0	4.0	4.1	2.8
<i>in % of Sales</i>	4.1%	3.8%	3.5%	3.3%	3.0%	2.7%	2.4%	1.6%
Change in Liquidity from								
- Working Capital	-0.3	-0.8	-1.9	-1.9	-3.1	-3.3	-3.5	0.0
- Capex	-1.7	-1.8	-1.8	-1.8	-2.0	-2.3	-2.5	-2.8
<i>Capex in % of Sales</i>	2.2%	2.1%	1.8%	1.5%	1.5%	1.5%	1.5%	1.6%
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free Cash Flow (WACC model)	6.6	9.5	10.7	12.9	14.2	16.1	17.6	19.4
WACC	8.3%	8.3%	8.3%	8.3%	8.3%	8.3%	8.3%	8.3%
Present value	6.7	8.9	9.2	10.3	10.5	11.0	11.1	195.8
Total present value	6.7	15.7	24.9	35.2	45.7	56.7	67.8	263.6

Valuation

Total present value (Tpv)	263.6
Terminal Value	195.8
Share of TV on Tpv	74%
Liabilities	32.3
Liquidity	22.9
Equity value	254.2

Growth: sales and margin

Short term: Sales growth	2020-2023	14.2%
Mid term: Sales growth	2020-2026	13.6%
Long term: Sales growth	from 2027	2.5%
Short term: Margin growth	2020-2023	13.9%
Mid term: Margin growth	2020-2026	15.1%
Long term: Margin growth	from 2027	16.0%

Number of shares (mln)

Number of shares (mln)	5.69
Value per share (EUR)	44.66

+Upside / -Downside

+Upside / -Downside	12%
Share price	39.90

Model parameter

Debt ratio	30.0%
Costs of Debt	5.0%
Market return	9.0%
Risk free rate	2.50%

Sensitivity Value per Share (EUR)

WACC	Terminal Growth				
	1.75%	2.25%	2.50%	2.75%	3.25%
8.76%	37.48	39.58	40.76	42.04	44.93
8.51%	39.02	41.33	42.63	44.03	47.25
8.26%	40.69	43.23	44.66	46.22	49.81
8.01%	42.50	45.29	46.88	48.61	52.63
7.76%	44.46	47.55	49.31	51.25	55.78

Sensitivity Value per Share (EUR)

WACC	EBIT-margin from 2027e				
	15.50%	15.75%	16.00%	16.25%	16.50%
8.76%	39.80	40.28	40.76	41.24	41.72
8.51%	41.61	42.12	42.63	43.13	43.64
8.26%	43.58	44.12	44.66	45.19	45.73
8.01%	45.73	46.31	46.88	47.45	48.02
7.76%	48.10	48.70	49.31	49.92	50.53

Source: Montega

P&L (in Euro m) Nynomic AG	2017	2018	2019	2020e	2021e	2022e
Sales	60.7	68.9	64.9	78.5	87.6	101.8
Increase / decrease in inventory	1.7	0.3	0.4	0.2	0.2	0.2
Own work capitalised	0.0	0.4	0.3	0.0	0.0	0.0
Total sales	62.4	69.6	65.5	78.7	87.8	102.1
Material Expenses	27.1	24.7	24.4	29.2	32.5	37.7
Gross profit	35.3	44.8	41.1	49.5	55.3	64.4
Personnel expenses	17.8	23.4	25.4	29.2	30.5	35.0
Other operating expenses	8.6	9.2	7.0	10.1	10.0	11.6
Other operating income	1.3	1.0	0.8	1.1	1.2	1.4
EBITDA	10.2	13.2	9.5	11.2	16.1	19.1
Depreciation on fixed assets	0.5	0.8	2.4	2.7	2.8	3.1
EBITA	9.7	12.5	7.2	8.6	13.3	16.1
Amortisation of intangible assets	0.3	0.6	0.8	0.5	0.5	0.5
Impairment charges and Amortisation of goodwill	0.2	0.0	0.0	0.0	0.0	0.0
EBIT	9.1	11.9	6.4	8.0	12.7	15.6
Financial result	-0.2	-0.3	-0.7	-0.9	-0.9	-0.8
Result from ordinary operations	9.0	11.6	5.8	7.1	11.9	14.7
Extraordinary result	0.0	0.0	0.0	0.0	0.0	0.0
EBT	9.0	11.6	5.8	7.1	11.9	14.7
Taxes	2.9	2.3	1.5	2.3	3.7	4.5
Net Profit of continued operations	6.1	9.3	4.3	4.8	8.2	10.2
Net Profit of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
Net profit before minorities	6.1	9.3	4.3	4.8	8.2	10.2
Minority interests	1.4	0.7	-0.1	0.3	0.4	0.4
Net profit	4.6	8.6	4.4	4.5	7.9	9.8

Source: Company (reported results), Montega (forecast)

P&L (in % of Sales) Nynomic AG	2017	2018	2019	2020e	2021e	2022e
Sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Increase / decrease in inventory	2.7%	0.4%	0.5%	0.2%	0.2%	0.2%
Own work capitalised	0.0%	0.5%	0.5%	0.0%	0.0%	0.0%
Total sales	102.8%	101.0%	101.0%	100.2%	100.2%	100.2%
Material Expenses	44.6%	35.9%	37.6%	37.2%	37.1%	37.0%
Gross profit	58.2%	65.0%	63.4%	63.0%	63.1%	63.2%
Personnel expenses	29.4%	34.0%	39.1%	37.2%	34.8%	34.4%
Other operating expenses	14.2%	13.3%	10.8%	12.9%	11.4%	11.4%
Other operating income	2.1%	1.5%	1.2%	1.4%	1.4%	1.4%
EBITDA	16.8%	19.2%	14.7%	14.3%	18.3%	18.8%
Depreciation on fixed assets	0.8%	1.1%	3.6%	3.4%	3.2%	3.0%
EBITA	15.9%	18.1%	11.1%	10.9%	15.1%	15.8%
Amortisation of intangible assets	0.5%	0.9%	1.2%	0.7%	0.6%	0.5%
Impairment charges and Amortisation of goodwill	0.4%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT	15.0%	17.2%	9.9%	10.2%	14.5%	15.3%
Financial result	-0.3%	-0.4%	-1.0%	-1.1%	-1.0%	-0.8%
Result from ordinary operations	14.7%	16.8%	8.9%	9.1%	13.5%	14.5%
Extraordinary result	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBT	14.7%	16.8%	8.9%	9.1%	13.5%	14.5%
Taxes	4.7%	3.3%	2.2%	2.9%	4.2%	4.4%
Net Profit of continued operations	10.0%	13.6%	6.6%	6.2%	9.4%	10.0%
Net Profit of discontinued operations	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net profit before minorities	10.0%	13.6%	6.6%	6.2%	9.4%	10.0%
Minority interests	2.4%	1.1%	-0.2%	0.4%	0.4%	0.4%
Net profit	7.6%	12.5%	6.8%	5.8%	9.0%	9.6%

Source: Company (reported results), Montega (forecast)

Balance sheet (in Euro m) Nynomic AG	2017	2018	2019	2020e	2021e	2022e
ASSETS						
Intangible assets	10.7	31.7	35.1	34.7	34.2	33.8
Property, plant & equipment	2.0	2.3	8.2	7.1	6.0	4.6
Financial assets	0.7	0.0	0.0	0.0	0.0	0.0
Fixed assets	13.4	34.0	43.3	41.8	40.2	38.5
Inventories	8.4	10.4	11.6	11.9	12.9	14.5
Accounts receivable	6.2	10.1	9.5	10.3	10.6	11.7
Liquid assets	19.6	11.1	10.6	27.8	34.9	43.2
Other assets	1.6	2.8	4.2	4.2	4.2	4.2
Current assets	35.8	34.4	35.9	54.2	62.6	73.6
Total assets	49.1	68.4	79.2	95.9	102.9	112.1
LIABILITIES AND SHAREHOLDERS' EQUITY						
Shareholders' equity	13.4	27.4	31.4	48.5	55.5	64.4
Minority Interest	3.3	2.3	1.5	0.5	0.5	0.5
Provisions	23.3	4.4	2.0	2.0	2.0	2.0
Financial liabilities	3.7	20.7	30.9	30.6	30.1	29.6
Accounts payable	2.4	2.1	3.6	4.4	4.9	5.7
Other liabilities	3.0	11.4	10.0	10.0	10.0	10.0
Liabilities	32.4	38.7	46.4	46.9	46.9	47.2
Total liabilities and shareholders' equity	49.1	68.4	79.2	95.9	102.9	112.1

Source: Company (reported results), Montega (forecast)

Balance sheet (in %) Nynomic AG	2017	2018	2019	2020e	2021e	2022e
ASSETS						
Intangible assets	21.7%	46.3%	44.3%	36.2%	33.3%	30.2%
Property, plant & equipment	4.1%	3.4%	10.3%	7.4%	5.8%	4.1%
Financial assets	1.4%	0.0%	0.0%	0.0%	0.0%	0.0%
Fixed assets	27.2%	49.7%	54.7%	43.6%	39.1%	34.3%
Inventories	17.2%	15.2%	14.7%	12.4%	12.5%	12.9%
Accounts receivable	12.7%	14.7%	12.0%	10.7%	10.3%	10.4%
Liquid assets	39.8%	16.2%	13.4%	28.9%	33.9%	38.5%
Other assets	3.2%	4.1%	5.3%	4.4%	4.1%	3.7%
Current assets	72.9%	50.2%	45.4%	56.5%	60.8%	65.7%
Total Assets	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
LIABILITIES AND SHAREHOLDERS' EQUITY						
Shareholders' equity	27.3%	40.0%	39.6%	50.5%	54.0%	57.5%
Minority Interest	6.8%	3.4%	1.8%	0.5%	0.5%	0.4%
Provisions	47.4%	6.5%	2.5%	2.0%	1.9%	1.7%
Financial liabilities	7.6%	30.3%	39.0%	31.9%	29.2%	26.4%
Accounts payable	4.9%	3.1%	4.5%	4.6%	4.8%	5.1%
Other liabilities	6.0%	16.7%	12.6%	10.4%	9.7%	8.9%
Total Liabilities	66.0%	56.6%	58.6%	48.9%	45.6%	42.1%
Total Liabilities and Shareholders' Equity	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Source: Company (reported results), Montega (forecast)


Statement of cash flows (in Euro m) Nynomic AG	2017	2018	2019	2020e	2021e	2022e
Net income	6.1	9.3	4.3	4.8	8.2	10.2
Depreciation of fixed assets	0.5	0.8	2.4	2.7	2.8	3.1
Amortisation of intangible assets	0.5	0.6	0.8	0.5	0.5	0.5
Increase/decrease in long-term provisions	2.1	-1.0	-2.3	0.0	0.0	0.0
Other non-cash related payments	1.9	0.0	-0.4	0.0	0.0	0.0
Cash flow	11.1	9.7	4.7	8.1	11.5	13.8
Increase / decrease in working capital	-2.1	-7.3	-1.2	-0.3	-0.8	-1.9
Cash flow from operating activities	9.0	2.4	3.6	7.8	10.7	11.9
CAPEX	-0.7	-1.7	-2.1	-1.7	-1.8	-1.8
Other	0.0	-23.7	-4.5	0.0	0.0	0.0
Cash flow from investing activities	-0.6	-25.4	-6.6	-1.7	-1.8	-1.8
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Change in financial liabilities	-1.5	16.3	3.0	-0.3	-0.5	-0.5
Other	-1.5	-2.0	-1.3	11.4	-1.3	-1.3
Cash flow from financing activities	-3.1	14.3	1.7	11.1	-1.8	-1.8
Effects of exchange rate changes on cash	3.8	0.3	0.9	0.0	0.0	0.0
Change in liquid funds	5.3	-8.7	-1.3	17.1	7.2	8.3
Liquid assets at end of period	19.5	11.1	10.6	27.8	34.9	43.2

Source: Company (reported results), Montega (forecast)


Key figures Nynomic AG	2017	2018	2019	2020e	2021e	2022e
Earnings margins						
Gross margin (%)	58.2%	65.0%	63.4%	63.0%	63.1%	63.2%
EBITDA margin (%)	16.8%	19.2%	14.7%	14.3%	18.3%	18.8%
EBIT margin (%)	15.0%	17.2%	9.9%	10.2%	14.5%	15.3%
EBT margin (%)	14.7%	16.8%	8.9%	9.1%	13.5%	14.5%
Net income margin (%)	10.0%	13.6%	6.6%	6.2%	9.4%	10.0%
Return on capital						
ROCE (%)	76.5%	43.4%	13.9%	15.3%	24.7%	30.4%
ROE (%)	33.9%	51.4%	14.9%	13.8%	16.1%	17.5%
ROA (%)	9.4%	12.6%	5.6%	4.7%	7.6%	8.7%
Solvency						
YE net debt (in EUR)	-13.0	9.6	20.2	2.8	-4.8	-13.6
Net debt / EBITDA	-1.3	0.7	2.1	0.3	-0.3	-0.7
Net gearing (Net debt/equity)	-0.8	0.3	0.6	0.1	-0.1	-0.2
Cash Flow						
Free cash flow (EUR m)	8.3	0.6	1.5	6.1	8.9	10.1
Capex / sales (%)	1.1%	1.5%	3.2%	2.2%	2.1%	1.8%
Working capital / sales (%)	18%	22%	28%	22%	21%	19%
Valuation						
EV/Sales	3.9	3.4	3.6	3.0	2.7	2.3
EV/EBITDA	23.2	17.9	24.8	21.1	14.7	12.4
EV/EBIT	25.9	19.9	36.8	29.5	18.6	15.2
EV/FCF	28.4	369.6	159.3	39.1	26.4	23.5
PE	41.1	23.3	45.9	46.4	28.9	23.2
P/B	17.0	8.3	7.2	4.7	4.1	3.5
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Company (reported results), Montega (forecast)


Sales development




Earnings development




Free-Cash-Flow development




Margin development



Capex / Working Capital



EBIT Yield / ROCE



DISCLAIMER

This document does not represent any offer or invitation to buy or sell any kind of securities or financial instruments. The document serves for information purposes only. This document only contains a non-binding opinion on the investment instruments concerned and non-binding judgments on market conditions at the time of publication. Due to its content, which serves for general information purposes only, this document may not replace personal, investor- or issue-specific advice and does also not provide basic information required for an investment decision that are formulated and expressed in other sources, especially in properly authorised prospectuses. All data, statements and conclusions drawn in this document are based on sources believed to be reliable but we do not guarantee their correctness or their completeness. The expressed statements reflect the personal judgement of the author at a certain point in time. These judgements may be changed at any time and without prior announcement. No liability for direct and indirect damages is assumed by either the analyst or the institution employing the analyst. This confidential report is made available to a limited audience only. This publication and its contents may only be disseminated or distributed to third parties following the prior consent of Montega. All capital market rules and regulations governing the compilation, content, and distribution of research in force in the different national legal systems apply and are to be complied with by both suppliers and recipients. Distribution within the United Kingdom: this document is allotted exclusively to persons who are authorized or appointed in the sense of the Financial Services Act of 1986 or on any valid resolution on the basis of this act. Recipients also include persons described in para 11(3) of the Financial Act 1986 (Investments Advertisements) (Exemptions) Order 1996 (in each currently valid amendment). It is not intended to remit information directly or indirectly to any other groups or recipients. It is not allowed to transmit, distribute, or to make this document or a copy thereof available to persons within the United States of America, Canada, and Japan or to their overseas territories.

Declaration according to Section 85 of the German Securities Trading Act (WpHG) and Art. 20 Regulation (EU) No. 596/2014 in conjunction with Commission Delegated Regulation (Delegierte Verordnung) 2016/958 (as of 10 March, 2021): Montega has made an agreement with this company about the preparation of a financial analysis. The research report has been made available to the company prior to its publication / dissemination. Thereafter, only factual changes have been made to the report. Montega AG and/or its affiliates have been bound to an agreement about investment banking services for this company during the past 12 months or, during that time, received remuneration for such services. A company affiliated with Montega AG may hold an interest in the issuer's share capital.

Prices of financial instruments mentioned in this analysis are closing prices of the publishing date (respectively the previous day) if not explicitly mentioned otherwise. Any updating of this publication will be made in the case of events that Montega considers to be possibly relevant to the stocks' price performance. The end of regular comments on events in context with the issuer (coverage) will be announced beforehand.

Sources of information: The main sources of information for the preparation of this financial analysis are publications of the issuer as well as publicly available information of national and international media, which Montega regards as reliable. There have also been discussions with members of the management team or the investor relations division of the company concerned when preparing this analysis.

Reference pursuant to MiFID II (as of 10 March, 2021): This publication was prepared on the basis of a contract between Montega AG and the issuer and will be paid by the issuer. This document has been widely published and Montega AG makes it simultaneously available for all interested parties. Its receipt therefore is considered a permissible minor non-monetary benefit in the sense of section 64 Paragraph 7 Sentence 2 No. 1 and 2 of the German Securities Trading Act (WpHG).

Fundamental basics and principles of the evaluative judgements contained in this document: Assessments and valuations leading to ratings and judgements given by Montega AG are generally based on acknowledged and broadly approved methods of analysis i.e. a DCF model, a peer group comparison, or sum-of-the-parts model.

Our ratings:

Buy: The analysts at Montega AG believe the share price will rise during the next twelve months.

Hold: Upside/downside potential limited. No immediate catalyst visible.

Sell: The analysts at Montega AG believe the share price will fall during the next twelve months.

Authority responsible for supervision:

Bundesanstalt für Finanzdienstleistungsaufsicht

Graurheindorfer Str. 108 und Marie-Curie-Str. 24-28

53117 Bonn

60439 Frankfurt

Contact Montega AG:

Schauenburgerstraße 10

20095 Hamburg

www.montega.de

Tel: +49 40 4 1111 37 80

Share price and recommendation history

Recommendation	Date	Price (EUR)	Price target (EUR)	Potential
Buy (Initiation)	01.04.2019	22.40	31.00	+38%
Buy	29.05.2019	17.80	30.00	+69%
Buy	13.08.2019	15.85	31.00	+96%
Buy	21.08.2019	15.00	31.00	+107%
Buy	27.09.2019	15.95	31.00	+94%
Buy	15.11.2019	17.25	27.00	+57%
Buy	21.11.2019	16.60	27.00	+63%
Buy	02.12.2019	17.25	27.00	+57%
Buy	05.03.2020	18.75	29.00	+55%
Buy	06.05.2020	16.35	29.00	+77%
Buy	18.05.2020	21.20	29.00	+37%
Buy	22.07.2020	22.00	31.00	+41%
Buy	14.09.2020	23.60	31.00	+31%
Buy	22.10.2020	23.20	31.00	+34%
Buy	27.10.2020	29.50	34.00	+15%
Buy	25.02.2021	37.40	45.00	+20%
Buy	10.03.2021	39.90	45.00	+13%